Biotech Values

[DewDiligence]

ABT -4.5% on the week despite the blowout results reported in HCV. The Bardoxalone termination (#msg-80651463) and ABT’s noncommittal comments about 2013 did the trick.

2012 non-GAAP EPS guidance was narrowed from the old range of $5.00-5.10 to the new range of $5.06-5.08, implying 4Q12 non-GAAP EPS of $1.50-1.52.

The AbbVie spinoff will trade with the ticker ABBV following the separation from ABT on 12/31/12.